Oxonium ion scanning mass spectrometry for large-scale plasma glycoproteomics.
Matthew E H WhiteLudwig R SinnD Marc JonesJoost de FolterSimran Kaur AulakhZiyue WangHelen R FlynnLynn KrügerPinkus Tober-LauVadim DemichevFlorian KurthMichael MullederVéronique BlanchardChristoph B MessnerMarkus RalserPublished in: Nature biomedical engineering (2023)
Protein glycosylation, a complex and heterogeneous post-translational modification that is frequently dysregulated in disease, has been difficult to analyse at scale. Here we report a data-independent acquisition technique for the large-scale mass-spectrometric quantification of glycopeptides in plasma samples. The technique, which we named 'OxoScan-MS', identifies oxonium ions as glycopeptide fragments and exploits a sliding-quadrupole dimension to generate comprehensive and untargeted oxonium ion maps of precursor masses assigned to fragment ions from non-enriched plasma samples. By applying OxoScan-MS to quantify 1,002 glycopeptide features in the plasma glycoproteomes from patients with COVID-19 and healthy controls, we found that severe COVID-19 induces differential glycosylation in IgA, haptoglobin, transferrin and other disease-relevant plasma glycoproteins. OxoScan-MS may allow for the quantitative mapping of glycoproteomes at the scale of hundreds to thousands of samples.
Keyphrases
- mass spectrometry
- liquid chromatography
- high resolution
- multiple sclerosis
- ms ms
- high performance liquid chromatography
- gas chromatography
- coronavirus disease
- sars cov
- capillary electrophoresis
- gene expression
- quantum dots
- magnetic resonance
- high resolution mass spectrometry
- dna methylation
- contrast enhanced
- binding protein
- simultaneous determination
- electronic health record
- aqueous solution